Back to Search
Study ID

100136

Clinical Study ID

CCR100136

Study Title A Phase IIb, 96 week, randomized, open-label multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, PK and antiviral effect of different doses and regimens of GW873140 in combination with Kaletra (lopinavir and ritonavir) in HIV-1 infected antiretroviral therapy naïve subjects
Clinicaltrials.gov Identifier NCT00102778
Sponsor ViiV Healthcare
Collaborators GSK
Phase phase 1
Study Recruitment Status Terminated
Generic Name aplaviroc
Trade Name
Study Indication Infection, Human Immunodeficiency Virus I

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.